Elapsed time for an unresolved adverse event: systemic anticancer therapy-induced neurotoxicity calls for action
- PMID: 32835811
- DOI: 10.1016/j.annonc.2020.08.2103
Elapsed time for an unresolved adverse event: systemic anticancer therapy-induced neurotoxicity calls for action
Conflict of interest statement
Disclosure AA: Advisory board or conference honoraria: Kyowa Kirin, BMS, MSD, Angelini, Pfizer, Accord, Roche. PB: Advisory board or conference honoraria: Merck, Sanofi, Merck Sharp & Dohme, Sun Pharma, Angelini, AstraZeneca, Bristol-Myers Squibb, Helsinn, GSK. DC: Speaker bureau/Scientific Advisor Roche, MSD, BMS, AZ, Boehringer Ingelheim, Amgen, Novartis.
Comment on
- 
  
  Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up.Ann Oncol. 2020 Oct;31(10):1306-1319. doi: 10.1016/j.annonc.2020.07.003. Epub 2020 Jul 30. Ann Oncol. 2020. PMID: 32739407 No abstract available.
 
        